TY - JOUR
T1 - Prevalence and Impact of Polyvascular Disease in Patients With Acute Myocardial Infarction in the Contemporary Era of Percutaneous Coronary Intervention ― Insights From the Japan Acute Myocardial Infarction Registry (JAMIR)
AU - JAMIR Investigators
AU - Arai, Riku
AU - Okumura, Yasuo
AU - Murata, Nobuhiro
AU - Fukamachi, Daisuke
AU - Honda, Satoshi
AU - Nishihira, Kensaku
AU - Kojima, Sunao
AU - Takegami, Misa
AU - Asaumi, Yasuhide
AU - Yamashita, Jun
AU - Saji, Mike
AU - Hibi, Kiyoshi
AU - Takahashi, Jun
AU - Sakata, Yasuhiko
AU - Takayama, Morimasa
AU - Sumiyoshi, Tetsuya
AU - Ogawa, Hisao
AU - Kimura, Kazuo
AU - Yasuda, Satoshi
AU - Takenaka, Takashi
AU - Tomita, Hirofumi
AU - Yokoyama, Hiroaki
AU - Ito, Tomonori
AU - Ishida, Masaru
AU - Koeda, Yorihiko
AU - Watanabe, Masafumi
AU - Watanabe, Tetsu
AU - Toshima, Taku
AU - Shimokawa, Hiroaki
AU - Sakata, Yasuhiko
AU - Takahashi, Jun
AU - Hao, Kiyotaka
AU - Sumiyoshi, Tetsuya
AU - Takayama, Masamori
AU - Kimura, Kazuo
AU - Kosuge, Masami
AU - Ebina, Toshiaki
AU - Suzuki, Hiroshi
AU - Maeda, Atsuo
AU - Ito, Masaaki
AU - Kurita, Tairo
AU - Masuda, Jun
AU - Tanigawa, Takashi
AU - Higaki, Jitsuo
AU - Nishimura, Kazuhisa
AU - Takahashi, Naohiko
AU - Akioka, Hidefumi
AU - Kawano, Kyoko
AU - Maemura, Koji
AU - Koide, Yuji
N1 - Publisher Copyright:
© 2024 Japanese Circulation Society. All rights reserved.
PY - 2024/6
Y1 - 2024/6
N2 - Background: This post hoc subanalysis aimed to investigate the impact of polyvascular disease (PolyVD) in patients with acute myocardial infarction (AMI) in the contemporary era of percutaneous coronary intervention (PCI). Methods and Results: The Japan Acute Myocardial Infarction Registry (JAMIR), a multicenter prospective registry, enrolled 3,411 patients with AMI between December 2015 and May 2017. Patients were classified according to complications of a prior stroke and/or peripheral artery disease into an AMI-only group (involvement of 1 vascular bed [1-bed group]; n=2,980), PolyVD with one of the complications (2-bed group; n=383), and PolyVD with both complications (3-bed group; n=48). The primary endpoint was all-cause death. Secondary endpoints were major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and major bleeding. In the 1-, 2-, and 3-bed groups, the cumulative incidence of all-cause death was 6.8%, 17.5%, and 23.7%, respectively (P<0.001); that of MACE was 7.4%, 16.4%, and 33.8% (P<0.001), respectively; and that of major bleeding was 4.8%, 10.0%, and 13.9% (P<0.001), respectively. PolyVD was independently associated with all-cause death (hazard ratio [HR] 2.21; 95% confidence interval [CI], 1.48–3.29), MACE (HR 2.07; 95% CI 1.40–3.07), and major bleeding (HR 1.68; 95% CI 1.04–2.71). Conclusions: PolyVD was significantly associated with worse outcomes, including thrombotic and bleeding events, in the contemporary era of PCI in AMI patients.
AB - Background: This post hoc subanalysis aimed to investigate the impact of polyvascular disease (PolyVD) in patients with acute myocardial infarction (AMI) in the contemporary era of percutaneous coronary intervention (PCI). Methods and Results: The Japan Acute Myocardial Infarction Registry (JAMIR), a multicenter prospective registry, enrolled 3,411 patients with AMI between December 2015 and May 2017. Patients were classified according to complications of a prior stroke and/or peripheral artery disease into an AMI-only group (involvement of 1 vascular bed [1-bed group]; n=2,980), PolyVD with one of the complications (2-bed group; n=383), and PolyVD with both complications (3-bed group; n=48). The primary endpoint was all-cause death. Secondary endpoints were major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and major bleeding. In the 1-, 2-, and 3-bed groups, the cumulative incidence of all-cause death was 6.8%, 17.5%, and 23.7%, respectively (P<0.001); that of MACE was 7.4%, 16.4%, and 33.8% (P<0.001), respectively; and that of major bleeding was 4.8%, 10.0%, and 13.9% (P<0.001), respectively. PolyVD was independently associated with all-cause death (hazard ratio [HR] 2.21; 95% confidence interval [CI], 1.48–3.29), MACE (HR 2.07; 95% CI 1.40–3.07), and major bleeding (HR 1.68; 95% CI 1.04–2.71). Conclusions: PolyVD was significantly associated with worse outcomes, including thrombotic and bleeding events, in the contemporary era of PCI in AMI patients.
KW - All-cause mortality
KW - Japan Acute Myocardial Infarction Registry (JAMIR)
KW - Major adverse cardiovascular events (MACE)
KW - Major bleeding
KW - Polyvascular disease
UR - http://www.scopus.com/inward/record.url?scp=85194442477&partnerID=8YFLogxK
U2 - 10.1253/circj.CJ-23-0477
DO - 10.1253/circj.CJ-23-0477
M3 - Article
C2 - 38008436
AN - SCOPUS:85194442477
SN - 1346-9843
VL - 88
SP - 911
EP - 920
JO - Circulation Journal
JF - Circulation Journal
IS - 6
ER -